专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210107998A1 COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF 有权
公开(公告)号：US20210107998A1
公开(公告)日：2021-04-15
申请号：US17076894
申请日：2020-10-22
申请人： Boehringer Ingelheim International GmbH , MacroGenics, Inc.
发明人： Sanjaya SINGH , Qi PAN , Rachel Rebecca BARRETT , Leslie S. JOHNSON , Pankaj GUPTA , Sarah LOW , Haixia WU
IPC分类号： C07K16/46 , C07K16/28 , C12N15/63 , C12N5/10 , C07K16/24
摘要： The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.

2. 发明申请

US20200207850A1 MULTI-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS 审中-公开
公开(公告)号：US20200207850A1
公开(公告)日：2020-07-02
申请号：US16818893
申请日：2020-03-13
申请人： MACROGENICS, INC.
发明人： Leslie S. JOHNSON , Ling HUANG , Gurunadh Reddy CHICHILI , Kalpana SHAH , Chia-Ying Kao LAM , Stephen James BURKE , Liqin LIU , Paul A. MOORE , Ezio BONVINI , Bhaswati BARAT
IPC分类号： C07K16/28 , C07K16/30
摘要： The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

3. 发明申请

US20190127471A1 NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：US20190127471A1
公开(公告)日：2019-05-02
申请号：US16092740
申请日：2017-04-13
申请人： MacroGenics, Inc.
发明人： Deryk T. LOO , Ling HUANG , Leslie S. JOHNSON , Thomas SON , Juniper SCRIBNER , Ezio BONVINI
IPC分类号： C07K16/28 , A61P35/00 , A61K47/68
摘要： The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that contain any of such B7-H3-binding molecules, and to methods involving the use of any of such B7-H3-binding molecules in the treatment of cancer and other diseases and conditions. The invention also particularly pertains to a molecule that comprises the human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety (a “B7-H3-ADC”). The invention is also directed to pharmaceutical compositions that contain such B7-H3-ADCs, and to methods involving the use of any of such B7-H3-ADCs in the treatment of cancer and other diseases and conditions.

4. 发明申请

US20180194840A1 COVALENT DIABODIES AND USES THEREOF 审中-公开
公开(公告)号：US20180194840A1
公开(公告)日：2018-07-12
申请号：US15911869
申请日：2018-03-05
申请人： MacroGenics, Inc.
发明人： Leslie S. JOHNSON , Ling HUANG
IPC分类号： C07K16/28
CPC分类号： C07K16/283 , C07K2317/34 , C07K2317/52 , C07K2317/626
摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through nonpeptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody like functionality to engineered into the molecule.

5. 发明申请

US20210130470A1 METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4 有权
公开(公告)号：US20210130470A1
公开(公告)日：2021-05-06
申请号：US17148309
申请日：2021-01-13
申请人： MACROGENICS, INC.
发明人： Leslie S. JOHNSON , Gurunadh Reddy CHICHILI , Kalpana SHAH , Ross LA MOTTE-MOHS , Paul A. Moore , Ezio Bonvini , Scott KOENIG
IPC分类号： C07K16/28 , C07K16/30 , C07K16/46 , C07K16/44 , A61K39/395 , A61P31/00 , A61P35/00
摘要： The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.

6. 发明申请

US20200062854A1 BISPECIFIC BINDING MOLECULES THAT ARE CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS, AND USES THEREOF 审中-公开
公开(公告)号：US20200062854A1
公开(公告)日：2020-02-27
申请号：US16488025
申请日：2018-02-22
申请人： MacroGenics, Inc.
发明人： Liqin LIU , Chia-Ying Kao LAM , Gundo DIEDRICH , Leslie S. JOHNSON , Paul A. MOORE , Ezio BONVINI
IPC分类号： C07K16/28 , C07K16/32 , A61P35/00 , A61K45/06 , A61K39/395
摘要： The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA. The CD137×TA Binding Molecules of the invention are capable of simultaneous binding to CD137, and a TA. The invention is directed to pharmaceutical compositions that contain any such CD137×TA Binding Molecules. The invention is additionally directed to methods for the use of such molecules in the treatment of cancer and other diseases and conditions. The invention also provides novel CD137-binding molecules, and HER2/neu-binding molecules, as well as derivatives thereof and uses thereof.

7. 发明申请

US20180148497A1 BISPECIFIC MOLECULES COMPRISING AN HIV-1 ENVELOPE TARGETING ARM 审中-公开
公开(公告)号：US20180148497A1
公开(公告)日：2018-05-31
申请号：US15514420
申请日：2015-09-29
申请人： Duke University , MacroGenics, Inc. , The University of North Carolina at Chapel Hill
发明人： Barton F. HAYNES , Guido FERRARI , Scott KOENIG , Leslie S. JOHNSON , Chia-Ying Kao LAM , Julia A. SUNG , David M. MARGOLIS , Liqin LIU , Jeffrey Lee NORDSTROM
IPC分类号： C07K16/10 , C07K16/28 , A61K39/42 , A61K45/06 , A61K39/395 , C07K16/46 , A61K39/00
摘要： The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式